DZ2114A1 - Procédé pour la préparation du d-tartrate de (-)-cis-6(s)-phényl-5}4-(2-pyrrolidine-1-ylethoxy)-phénylÜ-5,6,7,8-tétrahydronaphtalène-2-ol. - Google Patents

Procédé pour la préparation du d-tartrate de (-)-cis-6(s)-phényl-5}4-(2-pyrrolidine-1-ylethoxy)-phénylÜ-5,6,7,8-tétrahydronaphtalène-2-ol.

Info

Publication number: DZ2114A1
Authority: DZ; Algeria
Prior art keywords: phenylü; ylethoxy; tetrahydronaphthalene; pyrrolidine; tartrate
Prior art date: 1995-11-02

Application number

DZ960158A

Other languages

English (en)

Inventor

Charles K Chiu

Morgan Meltz

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-11-02

Filing date

1996-10-30

Publication date

2002-07-22

1996-10-30 Application filed by Pfizer filed Critical Pfizer

2002-07-22 Application granted granted Critical

2002-07-22 Publication of DZ2114A1 publication Critical patent/DZ2114A1/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- C07D295/084—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/088—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/18—Feminine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/30—Oestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/32—Antioestrogens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Reproductive Health (AREA)
Obesity (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Gynecology & Obstetrics (AREA)
Orthopedic Medicine & Surgery (AREA)
Vascular Medicine (AREA)
Dermatology (AREA)
Pregnancy & Childbirth (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Pyrrole Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DZ960158A 1995-11-02 1996-10-30 Procédé pour la préparation du d-tartrate de (-)-cis-6(s)-phényl-5}4-(2-pyrrolidine-1-ylethoxy)-phénylÜ-5,6,7,8-tétrahydronaphtalène-2-ol. DZ2114A1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US612595P	1995-11-02	1995-11-02

Publications (1)

Publication Number	Publication Date
DZ2114A1 true DZ2114A1 (fr)	2002-07-22

Family

ID=21719433

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DZ960158A DZ2114A1 (fr)	1995-11-02	1996-10-30	Procédé pour la préparation du d-tartrate de (-)-cis-6(s)-phényl-5}4-(2-pyrrolidine-1-ylethoxy)-phénylÜ-5,6,7,8-tétrahydronaphtalène-2-ol.

Country Status (43)

Country	Link
US (1)	US5948809A (fr)
EP (1)	EP0876359B1 (fr)
JP (1)	JP3088020B2 (fr)
KR (1)	KR19990067280A (fr)
CN (1)	CN1067065C (fr)
AP (1)	AP713A (fr)
AR (1)	AR004078A1 (fr)
AT (1)	ATE248827T1 (fr)
AU (1)	AU708841B2 (fr)
BG (1)	BG63943B1 (fr)
BR (1)	BR9611436A (fr)
CA (1)	CA2236673C (fr)
CO (1)	CO4770967A1 (fr)
CZ (1)	CZ287341B6 (fr)
DE (1)	DE69629837T2 (fr)
DK (1)	DK0876359T3 (fr)
DZ (1)	DZ2114A1 (fr)
EG (1)	EG21095A (fr)
ES (1)	ES2203713T3 (fr)
GT (1)	GT199600085A (fr)
HR (1)	HRP960503B1 (fr)
HU (1)	HU227521B1 (fr)
IL (1)	IL124027A (fr)
IS (1)	IS1855B (fr)
MA (1)	MA23998A1 (fr)
NO (1)	NO310358B1 (fr)
NZ (1)	NZ318498A (fr)
OA (1)	OA11009A (fr)
PE (1)	PE17698A1 (fr)
PL (1)	PL188633B1 (fr)
PT (1)	PT876359E (fr)
RO (1)	RO119829B1 (fr)
RU (1)	RU2162465C2 (fr)
SI (1)	SI0876359T1 (fr)
SK (1)	SK282172B6 (fr)
TN (1)	TNSN96134A1 (fr)
TR (1)	TR199800783T2 (fr)
TW (2)	TW581766B (fr)
UA (1)	UA51676C2 (fr)
UY (1)	UY24362A1 (fr)
WO (1)	WO1997016434A1 (fr)
YU (1)	YU49123B (fr)
ZA (1)	ZA969212B (fr)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
IL120266A (en) *	1996-02-28	2005-05-17	Pfizer	Use of estrogen antagonists and estrogen agonists in the preparation of medicaments for inhibiting pathological conditions
GB9703109D0 (en) *	1997-02-14	1997-04-02	Smith & Nephew	Compositions
HUP0102395A2 (hu) *	1998-06-16	2001-11-28	Pfizer Products Inc.	Izom- és csontrendszeri gyengeség kezelésére alkalmas szelektív ösztrogén receptor modulátorok és növekedési hormon szekretagógok (GHS) kombinációját tartalmazó gyógyszerkészítmények
ATE265853T1 (de) *	1998-06-16	2004-05-15	Pfizer Prod Inc	Kombinationstherapeutika, enthaltend einen selektiven östrogenrezeptormodulator und prostaglandin e2
AR018869A1 (es) *	1998-06-16	2001-12-12	Pfizer Prod Inc	Composicion farmaceutica, su uso para la preparacion de medicamentos y estuche que la contiene
YU26700A (sh) *	1999-05-24	2002-06-19	Pfizer Products Inc.	Postupak za cis-1-(2-(4-(6-metoksi-2-fenil-1,2,3,4- tetrahidronaftalen-1-il)fenoksi)etil)pirolidin
CO5271697A1 (es)	2000-01-12	2003-04-30	Pfizer Prod Inc	Composiciones y procedimientos para el tratamiento de afecciones que responden a un aumento de testosterona
CO5271696A1 (es) *	2000-01-12	2003-04-30	Pfizer Prod Inc	Procedimiento para reducir la morbilidad y el riesgo de mortalidad
CO5251465A1 (es)	2000-01-26	2003-02-28	Pfizer Prod Inc	Composiciones y procedimientos para tratar la osteoporosis y reducir el colesterol
PT1268453E (pt) *	2000-04-07	2006-10-31	Pfizer Prod Inc	Metabolitos de agonista/antagonista de estrogenio
US20020013327A1 (en) *	2000-04-18	2002-01-31	Lee Andrew G.	Compositions and methods for treating female sexual dysfunction
ES2274854T3 (es)	2000-05-08	2007-06-01	Pfizer Products Inc.	Resolucion enzimatica de moduladores selectivos del receptor de estrogeno.
IL145838A (en) *	2000-10-16	2008-11-03	Pfizer Prod Inc	Use of an estrogen agonist/antagonist for the manufacture of a medicament for treating vaginitis
TWI303990B (en)	2000-10-17	2008-12-11	Pfizer Prod Inc	New use of estrogen agonists/antagonists for improving vascular health
AU781168B2 (en) *	2001-01-26	2005-05-12	Pfizer Products Inc.	Method of treating certain cancers using an estrogen agonist/antagonist
AU2756602A (en) *	2001-04-25	2002-10-31	Pfizer Products Inc.	Methods and kits for treating depression or preventing deterioration of cognitive function
IL158390A0 (en)	2001-05-01	2004-05-12	Pfizer Prod Inc	Method for manufacturing a low dose pharmaceutical composition
CA2448235A1 (fr) *	2001-07-31	2003-02-13	Pfizer Products Inc.	Compositions pharmaceutiques, necessaires et methodes faisant intervenir des combinaisons d'agonistes/antagonistes des oestrogenes, d'oestrogenes et de progestines
RU2317104C2 (ru) *	2001-09-24	2008-02-20	Импиэриэл Инноувейшнс Лимитид	Способ модификации пищевого поведения и применение pyy или его агониста в качестве средства для модификации пищевого поведения
DK1487790T3 (da) *	2002-03-28	2010-05-10	Pfizer Prod Inc	Renset lasofoxifen og fremgangsmåde til opensning af racemisk lasofoxifen ved omkrystallisering
PA8576201A1 (es) *	2002-07-10	2004-05-26	Pfizer Prod Inc	Composicion farmaceutica que tiene una distribucion y potencia uniforme de farmaco
US7799273B2 (en)	2004-05-06	2010-09-21	Smp Logic Systems Llc	Manufacturing execution system for validation, quality and risk assessment and monitoring of pharmaceutical manufacturing processes
US7444197B2 (en)	2004-05-06	2008-10-28	Smp Logic Systems Llc	Methods, systems, and software program for validation and monitoring of pharmaceutical manufacturing processes
US20090118316A1 (en) *	2004-06-21	2009-05-07	Pfzer Inc.	Methods for Augmenting Bone
CA2570634A1 (fr) *	2004-06-30	2006-02-02	Eli Lilly And Company	I (indole-6-carbonyle-d-phenylglycinyle) -4- (l-methylpiperidine-4-yl) piperazine d- tartrate
CA2611035C (fr) *	2005-06-22	2010-09-14	Pfizer Products Inc.	Procede d'hydrogenation stereoselective la preparation de chlorhydrate de cis-6-phenyl-5-[4-(2-pyrrolidin-1-yl-ethoxy)-phenyl]-2-methoxy-5,6,7,8-tetrahydronaphtalene
CZ2007373A3 (cs) *	2007-05-29	2008-12-10	Zentiva, A. S	Zpusob prípravy lasofoxifenu
US8937188B2 (en)	2009-04-29	2015-01-20	Glenmark Generics Ltd.	Process for the preparation of lasofoxifene tartrate
KR101149529B1 (ko)	2009-09-11	2012-05-25	한국화학연구원	인덴온 유도체 및 이를 포함하는 약학적 조성물
CN103113323B (zh) *	2013-02-05	2015-11-11	南京华威医药科技开发有限公司	酒石酸拉索昔芬中间体的制备方法
NZ752443A (en)	2016-10-11	2022-11-25	Univ Duke	Lasofoxifene treatment of er+ breast cancer
CN117771239A (zh)	2018-04-10	2024-03-29	杜克大学	乳腺癌的拉索昔芬治疗
KR20220115062A (ko)	2021-02-09	2022-08-17	(주)오스티오뉴로젠	크로몬 구조의 화합물을 포함하는 골다공증의 예방 및 치료용 약학적 조성물
GB202116903D0 (en)	2021-11-18	2022-01-05	Sermonix Pharmaceuticals Inc	Lasofoxifene treatment of aromatase-resistant er+ cancer
AU2024328571A1 (en)	2023-08-21	2026-03-12	Duke University	Treatment of solid cancer with lasofoxifene
WO2026096820A1 (fr)	2024-10-30	2026-05-07	Sermonix Pharmaceuticals, Inc.	Traitement néoadjuvant du cancer du sein er+ avec du lasofoxifène
WO2026095931A1 (fr)	2024-10-30	2026-05-07	Sermonix Pharmaceuticals, Inc.	Traitement néoadjuvant du cancer du sein er+ avec du lasofoxifène

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3274213A (en) *	1961-09-05	1966-09-20	Upjohn Co	Alkoxy-substituted 2-phenyl-1-(tertiary-aminoalkoxy)phenyl-3, 4-dihydronaphthalenes
US3234090A (en) *	1962-09-10	1966-02-08	Ciba Geigy Corp	Pharmaceutical compositions comprising saturated basic ethers
US3522319A (en) *	1964-01-23	1970-07-28	Ciba Geigy Corp	Phenol substituted tetrahydronaphthalenes useful as estrogenics
US5552412A (en) *	1995-01-09	1996-09-03	Pfizer Inc	5-substitued-6-cyclic-5,6,7,8-tetrahydronaphthalen2-ol compounds which are useful for treating osteoporosis

1996
- 1996-04-10 UA UA98042214A patent/UA51676C2/uk unknown
- 1996-09-30 TW TW091125091A patent/TW581766B/zh not_active IP Right Cessation
- 1996-09-30 TW TW085111903A patent/TW518327B/zh not_active IP Right Cessation
- 1996-10-04 SI SI9630635T patent/SI0876359T1/xx unknown
- 1996-10-04 KR KR1019980703251A patent/KR19990067280A/ko not_active Ceased
- 1996-10-04 RU RU98110128/04A patent/RU2162465C2/ru active
- 1996-10-04 NZ NZ318498A patent/NZ318498A/xx not_active IP Right Cessation
- 1996-10-04 ES ES96931206T patent/ES2203713T3/es not_active Expired - Lifetime
- 1996-10-04 DE DE69629837T patent/DE69629837T2/de not_active Expired - Lifetime
- 1996-10-04 PT PT96931206T patent/PT876359E/pt unknown
- 1996-10-04 RO RO98-00926A patent/RO119829B1/ro unknown
- 1996-10-04 EP EP96931206A patent/EP0876359B1/fr not_active Expired - Lifetime
- 1996-10-04 CN CN96198048A patent/CN1067065C/zh not_active Expired - Lifetime
- 1996-10-04 SK SK542-98A patent/SK282172B6/sk not_active IP Right Cessation
- 1996-10-04 US US09/065,094 patent/US5948809A/en not_active Expired - Lifetime
- 1996-10-04 WO PCT/IB1996/001049 patent/WO1997016434A1/fr not_active Ceased
- 1996-10-04 DK DK96931206T patent/DK0876359T3/da active
- 1996-10-04 TR TR1998/00783T patent/TR199800783T2/xx unknown
- 1996-10-04 BR BR9611436A patent/BR9611436A/pt not_active Application Discontinuation
- 1996-10-04 HU HU9900087A patent/HU227521B1/hu unknown
- 1996-10-04 IL IL12402796A patent/IL124027A/en not_active IP Right Cessation
- 1996-10-04 PL PL96326498A patent/PL188633B1/pl unknown
- 1996-10-04 AU AU69984/96A patent/AU708841B2/en not_active Expired
- 1996-10-04 CA CA002236673A patent/CA2236673C/fr not_active Expired - Lifetime
- 1996-10-04 CZ CZ19981320A patent/CZ287341B6/cs not_active IP Right Cessation
- 1996-10-04 JP JP09517180A patent/JP3088020B2/ja not_active Expired - Lifetime
- 1996-10-04 AT AT96931206T patent/ATE248827T1/de active
- 1996-10-11 GT GT199600085A patent/GT199600085A/es unknown
- 1996-10-23 AR ARP960104862A patent/AR004078A1/es active IP Right Grant
- 1996-10-29 HR HR960503A patent/HRP960503B1/xx not_active IP Right Cessation
- 1996-10-30 DZ DZ960158A patent/DZ2114A1/fr active
- 1996-10-30 TN TNTNSN96134A patent/TNSN96134A1/fr unknown
- 1996-10-30 PE PE1996000753A patent/PE17698A1/es not_active Application Discontinuation
- 1996-10-30 EG EG95996A patent/EG21095A/xx active
- 1996-10-30 MA MA24381A patent/MA23998A1/fr unknown
- 1996-10-31 AP APAP/P/1996/000880A patent/AP713A/en active
- 1996-11-01 CO CO96057925A patent/CO4770967A1/es unknown
- 1996-11-01 ZA ZA9609212A patent/ZA969212B/xx unknown
- 1996-11-01 YU YU57896A patent/YU49123B/sh unknown
- 1996-11-04 UY UY24362A patent/UY24362A1/es unknown
1998
- 1998-04-16 IS IS4718A patent/IS1855B/is unknown
- 1998-04-29 OA OA9800046A patent/OA11009A/en unknown
- 1998-04-30 NO NO19981962A patent/NO310358B1/no not_active IP Right Cessation
- 1998-05-21 BG BG102474A patent/BG63943B1/bg unknown

Also Published As

Publication number	Publication date
TW581766B (en)	2004-04-01
AP9600880A0 (en)	1997-01-31
CN1201458A (zh)	1998-12-09
BG63943B1 (bg)	2003-07-31
RU2162465C2 (ru)	2001-01-27
PL188633B1 (pl)	2005-03-31
CO4770967A1 (es)	1999-04-30
TR199800783T2 (xx)	1998-08-21
BG102474A (en)	1999-06-30
TNSN96134A1 (fr)	1998-12-31
HUP9900087A2 (hu)	1999-05-28
UA51676C2 (uk)	2002-12-16
CN1067065C (zh)	2001-06-13
NZ318498A (en)	1999-06-29
GT199600085A (es)	1998-04-04
EG21095A (en)	2000-10-31
HRP960503B1 (en)	2001-12-31
SK282172B6 (sk)	2001-11-06
HUP9900087A3 (en)	1999-11-29
PT876359E (pt)	2003-12-31
ZA969212B (en)	1998-05-04
OA11009A (en)	2003-03-03
AU708841B2 (en)	1999-08-12
CA2236673A1 (fr)	1997-05-09
MX9803544A (es)	1998-09-30
CA2236673C (fr)	2002-03-19
WO1997016434A1 (fr)	1997-05-09
SI0876359T1 (en)	2003-12-31
NO981962D0 (no)	1998-04-30
AP713A (en)	1998-12-28
IL124027A (en)	2001-10-31
HU227521B1 (en)	2011-07-28
EP0876359B1 (fr)	2003-09-03
AU6998496A (en)	1997-05-22
IS1855B (is)	2003-02-21
PL326498A1 (en)	1998-09-28
JPH11502866A (ja)	1999-03-09
YU57896A (sh)	1998-12-23
RO119829B1 (ro)	2005-04-29
KR19990067280A (ko)	1999-08-16
SK54298A3 (en)	1999-07-12
MA23998A1 (fr)	1997-07-01
CZ287341B6 (en)	2000-10-11
US5948809A (en)	1999-09-07
YU49123B (sh)	2004-03-12
UY24362A1 (es)	1997-04-24
IS4718A (is)	1998-04-16
DE69629837T2 (de)	2004-05-06
AR004078A1 (es)	1998-09-30
HRP960503A2 (en)	1998-04-30
DK0876359T3 (da)	2003-11-24
EP0876359A1 (fr)	1998-11-11
NO981962L (no)	1998-04-30
PE17698A1 (es)	1998-04-18
NO310358B1 (no)	2001-06-25
TW518327B (en)	2003-01-21
CZ132098A3 (cs)	1999-03-17
BR9611436A (pt)	1999-03-23
ES2203713T3 (es)	2004-04-16
JP3088020B2 (ja)	2000-09-18
ATE248827T1 (de)	2003-09-15
DE69629837D1 (de)	2003-10-09

Publication	Publication Date	Title
MA23998A1 (fr)	1997-07-01	Procede pour la preparation du d-tartrate de (-) cis-6 (s) -phenyl -5 (r) -[4-(2-pyrrolidine-1-ylethoxy)- phenyl] -5,6,7,8-tetrahydronaphtalene -2-01
DZ2074A1 (fr)	2002-07-22	Formulation nouvelle contenant de la paroxétine, et procédé pour sa préparation.
DZ2247A1 (fr)	2002-12-18	Procédé pour la préparation du sildénafil.
DZ3079A1 (fr)	2004-10-24	Procédé pour la préparation de 4-carboxy-amino-2-substitué-1,2,3,4 tétrahydroquinolé.
DZ1911A1 (fr)	2002-02-17	Procédé pour la synthèse de sulfoxydes substitues.
MA23143A1 (fr)	1994-10-01	Procede pour la preparation de compositions vaccinantes .
NO981800L (no)	1998-06-11	FremgangsmÕte for fremstilling av 1,1,1,3,3-pentafluorpentan
DZ2217A1 (fr)	2002-12-03	Dérivés d'imidazole substitués, procédé pour leur préparation et compositions les contenant.
FR2707087B1 (fr)	1995-10-13	Nouveau procédé de préparation de l'ergothionéine.
DZ2141A1 (fr)	2002-07-23	Procédés intermédiares pour la préparation de 1-benzyl-4-(5,6-diméthoxy-1-indanone)-2-yi)méthylpipéridine.
EP0671454A3 (fr)	1996-08-21	Procédé pour l'élimination d'hétéroatomes.
DZ2044A1 (fr)	2002-07-21	5,6-Dihydro-9h-pyrazolo Ä3,4-cÜ-1,2,4-triazol Ä4,3-alphaÜpyridines tricycliques procédé pour leur préparation et compositions les contenant.
DZ1758A1 (fr)	2002-02-17	Procédé pour la préparation d'aryl-piperidine carbinols.
DZ2032A1 (fr)	2002-07-21	Un procédé pour la préparation de l'hydrochlorure de lercanidipine.
DZ1946A1 (fr)	2002-02-17	Procédé pour la préparation de supports.
EP0657438A3 (fr)	1995-10-11	Procédé pour la préparation d'alkylesulfinylbenzamides et de 1,2-benzoisothiazol-3-ones.
FR2721598B1 (fr)	1996-08-23	Procédé de préparation de catalyseurs d'ammoxydation.
FR2714063B1 (fr)	1996-03-08	Procédé de préparation de collagène à partir de cnidaires, et compositions obtenues utilisables en cosmétique.
EP0729938A3 (fr)	1997-08-20	Procédé pour la préparation d'aryle-alkyle-hydropéroxydes
FR2708266B1 (fr)	1997-01-10	Procédé de préparation d'alcanesulfonamides.
FR2733227B1 (fr)	1997-07-04	Procede pour la preparation de 1,1-difluoroethane
FR2715656B1 (fr)	1996-03-22	Procédé de préparation d'anhydride citraconique.
FR2659665B1 (fr)	1992-07-24	Procede d'affinage, notamment de decuivrage, du plomb.
EP0470462A3 (en)	1992-06-17	Process for the preparation of halogenated methylketones, especially 1,1,1-trifluoracetone
EP0610963A3 (fr)	1995-04-19	Procédé pour la préparation de 1,1,1,2-tétrafluoroéthane.